Utilizing preclinical models, the research identifies chromatin landscape alterations driven by constitutive JAK2 activation, which enhance NF-κB signaling and chronic inflammation, a hallmark of MPN pathogenesis. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.